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This article reformulates a common illness-death model in terms of a new
system of stochastical differential equations (SDEs). The SDEs are used to
estimate epidemiological characteristics and burden of systemic lupus ery-
thematosus in England and Wales in 1995.
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1 Introduction
With a view to basic epidemiological parameters such as incidence, prevalence and mor-
tality of a disease, it has proven useful to consider so called state models or compartmen-
tal models. The model used here is also termed illness-death model (Kalbfleisch and Prentice,
2002, Fig. 8.4). It consists of the three states Normal, Disease, Death and the transi-
tions between the states. Normal means non-diseased with respect to the disease under
consideration. The numbers of persons in the Normal and Disease state are denoted as
S (susceptibles) and C (cases), respectively. The transition intensities (synonymously:
rates) are called as shown in Figure 1: i is the incidence rate, m0 and m1 are the
mortality rates of the non-diseased and diseased persons, respectively. In general, the
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intensities depend on calendar time t, age a and sometimes also on the duration d of the
disease.
Figure 1: Illness-death model of a chronic disease with three states. Persons in the
state Normal are healthy with respect to the considered disease. In the state
Disease they suffer from the disease. In the most general case, the transition
rates depend on the calendar time t, age a, and in case of the disease-specific
mortality m1 also on the disease’s duration d.
When the rates do not depend on calendar time t, the model is called time-homogeneous.
Then, with the additional condition that there is no dependency on the duration,
Murray and Lopez have considered a two-dimensional system of ordinary differential
equations (ODEs) to relate the changes of the numbers of healthy and diseased persons
with the rates of the in- and outflows of the corresponding states (1994)1:
dS
da
= −
(
i(a) +m0(a)
)
· S
dC
da
= i(a) · S −m1(a) · C.
(1)
1Murray and Lopez did not report the exact equations, but from a publication two years later it may
be deduced that they use an approach similar to Eq. (1).
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Age a plays the role of temporal progression. The linear system (1) looks relatively
harmless, but the impression is misleading. Mostly only the age-specific mortality of the
general population is well known, and rate m1 is epidemiologically accessible as relative
risk. Then, the system becomes nonlinear.
Furthermore, the inclusion of the hypothetical values S and C is disturbing. It would
be better if we had the age-specific prevalence p(a) := C(a)S(a)+C(a) here, what indeed can
be achieved (Brinks, 2011).
What are the benefits of such ODEs? For smooth incidence- and mortality rates
plus an initial condition, the age profile of the numbers of patients or the prevalence is
uniquely determined. To state it clearly, the “forces” incidence and mortality uniquely
prescribe the prevalence – not only qualitatively but in these quantitative terms. In this,
we speak of the forward problem: we close from the causes – the forces – to the effect,
namely the number of diseased persons. The reverse way, closing from the numbers of
diseased persons to the incidence, is the inverse problem – we infer from the effect to
the cause.
This paper is structured as follows: in the next section we describe the illness-death
model of Figure 1 in terms a new system of two stochastic differential equations (SDEs).
As an application, in Section 3 we solve a forward problem to estimate the age-specific
prevalence of systemic lupus erythematosus (SLE) in England and Wales from published
data. This allows calculation of the mean age at onset of SLE, the mean duration and
the burden of SLE in terms of diseased persons.
2 Stochastic description of the illness-death model
What can be achieved in the domain of ODEs, dividing the number C(a) of the diseased
by the number S(a)+C(a) of the living for deriving the prevalence at age a, is not that
easy in random variables. Distributions of quotients of stochastically dependent random
variables are problematic, so we have to model S and C bivariately.
Let X(a) := (S(a), C(a))t be the composite vector (the superscript denotes transpo-
sition). For ∆a > 0 define the vector ∆X of increments:
∆X(a) :=
(
S(a+∆a)− S(a), C(a+∆a)− C(a)
)t
Now we follow the reasoning of (Allen, 1999) and (Allen, 2008), who have applied the
theory presented here in the field of infectious diseases modeling.
Choose ∆a > 0 small that at most one person can change the state. In accordance with
the definition of the rates i, m0 and m1 the following assumptions about the probability
distribution P (∆X(a)) are made:
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P(
∆X(a) =
(
u
v
))
=


m0(a) · S(a) ·∆a+ o(∆a) if (u, v) = (−1, 0)
m1(a) · C(a) ·∆a+ o(∆a) if (u, v) = (0,−1)
i(a) · S(a) ·∆a+ o(∆a) if (u, v) = (−1, 1)
1−
[
m0(a) · S(a) +m1(a) · C(a)+
i(a) · S(a)
]
·∆a+ o(∆a) if (u, v) = (0, 0)
(2)
If we further assume that the increments are normally distributed, we get the expected
value
E
(
∆X(a)
)
=
[
m0(a) · S(a) ·
(
−1
0
)
+m1(a) · C(a) ·
(
0
−1
)
+ i(a) · S(a) ·
(
−1
1
)]
·∆a+o(∆a)
and covariance matrix
V
(
∆X(a)
)
= E
(
∆X(a) ·∆Xt(a)
)
− E (∆X(a)) ·E
(
∆Xt(a)
)
≈ E
(
∆X(a) ·∆Xt(a)
)
.
The matrix V is symmetric and positively definite. Hence, there is uniquely determined
matrix square root V 1/2. Due the normal distribution assumption the vector X fulfills
X(a+∆a) = X(a) + ∆X(a) = X(a) + E
(
∆X(a)
)
+ V
(
∆X(a)
)1/2
ξ, (3)
where ξ = (ξ1, ξ2)
t has normally distributed components ξi ∼ N(0, 1), i = 1, 2.
Under certain smoothness conditions about the coefficient functions i,m1 and m0 the
difference equation (3) is an Euler approximation to the Iˆto SDE system
dS
da
= −
(
i(a) +m0(a)
)
·S + b11
dW1
da
+ b12
dW2
da
dC
da
= i(a) · S −m1(a) · C + b21
dW1
da
+ b22
dW2
da
.
(4)
In this expression, W1 and W2 are independent Wiener processes (Kloeden and Platen,
1999) and the 2 × 2 – matrix B = (bij) is the uniquely determined square root of the
covariance matrix divided by ∆a:
B =
(
V (∆X)/∆a
)1/2
.
Which advantages has the SDE formulation compared to the ODE? In rare diseases
as in the next section, the inclusion of uncertainty is sometimes more appropriate than
calculating deterministically. In addition, SDEs sometimes have properties that can-
not be derived from the theory of ODEs, as for example the quasistationary solutions
(Darroch and Seneta, 1967).
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3 Application to Systemic Lupus Erythematosus
In this section the SDE is applied to epidemiological data of systemic lupus erythemato-
sus in England and Wales. Systemic lupus erythematosus (SLE) is a severe rheumatic
disease with a variety of clinical manifestations. Despite several therapy options, pa-
tients often are restricted heavily in quality of life and ability to work. Epidemiological
data are rare. Here, the incidence data for males and females is taken from the UK
General Practice Research Database (GPRD) in the years 1990–1999 as reported in
(Somers et al., 2007). Mortality m1 of SLE patients is modeled by the relative mortality
as reported in (Bernatsky et al., 2006). Duration of SLE was not taken into account.
Regarding the mortality of the non-diseased, we take the mortality in the general pop-
ulation. Due to the low prevalence of SLE this is legitimate. Then, 5000 solution paths of
the SDE system (4) are simulated by the Euler-Maruyama method (Kloeden and Platen,
1999) and the corresponding age-specific prevalences have been calculated. This is done
for males and females separately.
As an example, Figure 2 shows the prevalence resulting from two pairs of solution
paths.
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Figure 2: Example paths of the age-specific prevalence of SLE resulting from two pairs
of solution paths of system (4).
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Of course, single paths for the prevalence are not that important. It is more interesting,
to analyze where the paths of the prevalence lie and what the charcteristics are. As an
example, Figures 3 and 4 show the regions where 95% of the 5000 solution paths lie.
The upper and the lower dotted curve indicate the 97.5% and 2.5% quantile of the 5000
prevalence paths, respectively. This means, for each age a the corresponding quantiles
from the empirical distribition of the 5000 values at age a are calculated. Additionally,
Figures 3 and 4 show the curve of the median (solid line).
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Figure 3: Age-specific prevalence of SLE
in males.
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Figure 4: Age-specific prevalence of SLE
in females.
The median curves of males and females indicate the big difference of prevalent SLE
between males and females. This is due to the fact, that gender is a risk factor for SLE
and incidence between males and females differ strongly. The hazard ratio (females vs.
males) is about 10 in the age-group of 25-35 years. The hazard ratio decreases to about
5 in the following age-classes until 65 years and after that lowers to about 2.
For an estimate of the burden of SLE in England and Wales one may estimate the
total number C of persons with SLE:
C =
90∑
a=0
p(a) ·N(a), (5)
whereN(a) denotes the number of persons in England and Wales aged a = 0, . . . , 90. The
numberN(a) is obtained from official vital statistics in the year 1995, (Office for National Statistics,
2011). The age-specific prevalence p(a) is taken from the 5000 paths.
Figures 5 and 6 show the distributions of C obtained from the 5000 paths. Again, the
enormous difference between males and females becomes obvious. While 50.1 thousand
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Figure 5: Histogram of the number of
males with SLE.
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Figure 6: Histogram of the number of fe-
males with SLE.
females are affected in England and Wales (interquartile range (IQR): 40.3–60.9), for
males the corresponding number is 9.2 (IQR: 6.6–12.5) thousand.
In situation described here, it is possible to derive the mean duration D of SLE in
males and females. The mean duration D is the number of person-years of all SLE
patients divided by the total number of persons who ever got it:
D =
90∑
a=0
p(a) ·N(a)
90∑
a=0
i(a) ·
(
1− p(a)
)
·N(a)
. (6)
If we calculate this value for all paths p, we find that in males and females the mean
duration is 23.2 (IQR: 16.7–31.5) and 23.9 (IQR: 16.2–29.1) years, respectively. Thus,
genders do not differ much in that respect. Similarly, the mean age at onset M may be
computed:
M =
90∑
a=0
a · i(a) ·
(
1− p(a)
)
·N(a)
90∑
a=0
i(a) ·
(
1− p(a)
)
·N(a)
. (7)
The empirical distribution of M in the 5000 paths yields 51.750 (IQR: 51.748–51.752)
and 46.108 (46.102–46.113) years in males and females, respectively. It is striking that
M has a relativly low variability in both genders. This is due to the factor 1 − p(a),
which is close to unity.
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4 Conclusion
In the domain of infectious diseases, the theory of deterministic differential equations
was generalized towards stochastic differential equations more than a decade ago, (Allen,
1999). In this article this transformation has been accomplished in the field of chronic
diseases. The numbers of healthy and diseased persons have been modeled by a new sys-
tem of two Iˆto stochastic differential equations. In rare chronic diseases such as systemic
lupus erythematosus, a stochastic formulation might be preferable over a deterministic.
Even if the incidence and mortality rates are well-known, statistical fluctuations in the
number of diseased have a strong impact in the age course of the prevalence. This be-
comes obvious in Figures 5 and 6 where the distribution of the total number of males
and females with SLE in England and Wales in 1995 have been estimated. The middle
fifty spans about 6 and 20 thousand males and females respectively. Additionally, other
disease characteristics have been calculated. The mean age at onset as derived in our
theoretical model is 51.8 and 46.1 for males and females, respectively. The corrspond-
ing empirical values 52.2 and 46.3 observed in the register data by Somers et al. are in
good agreement. Another hint for the appropriateness of the methods described here
comes from the basic epidemiological equation, that overall prevalence equals the prod-
uct of overall incidence and duration of the disease (Szklo and Nieto, 2007). The overall
prevalence in males and females can easily be obtained by Eq. (5) and the age pyramid
N(a). In our model the overall prevalence divided by the mean duration (Eq. (6))
yields the overall incidence 1.58 and 7.95 per 100000 person-years for males and females,
respectively. Again, this is close to the empirically observed values 1.60 and 8.01 per
100000 person-years (Somers et al., 2007, Tab. 1). When relating the results of this
study to other epidemiological data from the UK, especially the overall incidence for
females appears high. Hopkinson et al. find a value of about 6.5 per 100000 person-
years only (1993). However, it has to be noted that the data of (Hopkinson et al., 1993)
are in a way inconsistent: If we calculate the mean duration of SLE in females by the
basic epidemiological equation for the data of Hopkinson et al., we find a mean duration
of about 7 years only, which contradicts common survival times of persons with SLE
(Cervera et al., 2003).
Although there is an ongoing debate about the differences between childhood-onset
SLE and adult-onset as well as duration of SLE as a risk factor for comorbidities and
mortality, it has to be noticed that reliable epidemiologic data about age at onset, du-
ration of the disease, mean age of diseased etc are sparse or lacking. As an example, the
sytematic review (Danchenko et al., 2006) about the global burden and epidemiology of
SLE just found one study from Germany, the European country with the most inhabi-
tants. The associated publication (Zink et al., 2001) was about prevalent cases, but did
not mention a prevalence estimate. Incidence had not been adressed.
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Theoretical models such as the one presented here may help to at least roughly es-
timate the burden and characteristics of rare chronic diseases. This is especially true
in countries with few epidemiological or administrative data. However, the approach
described here has several limitations. First, the stochastic differential equation (4) does
not take into account calendar time trends. In the application to SLE, it has been shown
that relative mortality of SLE patients undergoes a secular trend, (Bernatsky et al., 2006,
Tab. 6). In the same publication we find, that relative mortality in persons with SLE
depends on the duration of the disease. The longer a person is diseased, the more the
relative risk decreases. Duration dependence is not modeled in Eq. (4). Hence, the new
approach may be used as an approximation only, and more evaluations of the method
are necessary to examine validity and applicability of the model. However, the disease
characteristics derived by the new methods in this work are consistent and indicate an
interesting and maybe fruitful way to go.
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